Skip to main content
Erschienen in: Spektrum der Augenheilkunde 1/2016

01.02.2016 | konsensusbericht

Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa

verfasst von: a. Univ. Prof. Dr. Michael Stur, Siamak Ansari-Shahrezaei, Anton Haas, Michael Tittl

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Chorioretinopathia centralis serosa (CCS) ist eine meist akut auftretende, exsudative Erkrankung der Makula, die primär junge Männer betrifft, aber auch bei Schwangeren und bei Frauen in der Menopause auftreten kann. In den meisten Fällen kommt es zu einer Spontanremission, die wahrscheinlich durch gezielte Aufklärung des Patienten erleichtert werden kann. Heilt die CCS nicht innerhalb von 3 Monaten ab, sollte die Durchführung einer photodynamischen Therapie mit reduzierter Laser- oder Medikamentendosis erwogen werden. Auf die Verordnung anderer Medikamente sollte verzichtet werden, weil es einerseits keine nachweislich wirksamen Medikamente gibt, andererseits durch Medikamenteneinnahme die wahrscheinlich viel wirksamere Veränderung des Lebensstils in den Hintergrund tritt.
Literatur
1.
Zurück zum Zitat Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144(1):46–50.PubMedCrossRef Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144(1):46–50.PubMedCrossRef
2.
Zurück zum Zitat Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73.PubMedCrossRef Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73.PubMedCrossRef
3.
Zurück zum Zitat Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201–14.PubMedCrossRef Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201–14.PubMedCrossRef
4.
Zurück zum Zitat Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26.PubMedCentralPubMedCrossRef Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110(4):698–703.PubMedCrossRef Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110(4):698–703.PubMedCrossRef
6.
Zurück zum Zitat Pastor-Idoate S, Pena D, Herreras JM. Adrenocortical adenoma and central serous chorioretinopathy: a rare association? Case Rep Ophthalmol. 2011;2(3):327–32.PubMedCentralPubMedCrossRef Pastor-Idoate S, Pena D, Herreras JM. Adrenocortical adenoma and central serous chorioretinopathy: a rare association? Case Rep Ophthalmol. 2011;2(3):327–32.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Miki A, Kondo N, Yanagisawa S, et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–72.PubMedCrossRef Miki A, Kondo N, Yanagisawa S, et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–72.PubMedCrossRef
8.
Zurück zum Zitat de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122(3):562–70.PubMedCrossRef de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122(3):562–70.PubMedCrossRef
9.
Zurück zum Zitat Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3.PubMedCrossRef Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3.PubMedCrossRef
10.
Zurück zum Zitat Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–13.PubMedCrossRef Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–13.PubMedCrossRef
11.
Zurück zum Zitat Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–4.PubMedCentralPubMedCrossRef Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–4.PubMedCentralPubMedCrossRef
12.
13.
Zurück zum Zitat Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431–48.PubMedCrossRef Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431–48.PubMedCrossRef
14.
Zurück zum Zitat Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol. 1974;77(2):158–60.PubMedCrossRef Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol. 1974;77(2):158–60.PubMedCrossRef
15.
Zurück zum Zitat Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–8.PubMedCrossRef Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–8.PubMedCrossRef
16.
Zurück zum Zitat Lovallo WR, Al’Absi M, Blick K, Whitsett TL, Wilson MF. Stress-like adrenocorticotropin responses to caffeine in young healthy men. Pharmacol Biochem Behav. 1996;55(3):365–9.PubMedCrossRef Lovallo WR, Al’Absi M, Blick K, Whitsett TL, Wilson MF. Stress-like adrenocorticotropin responses to caffeine in young healthy men. Pharmacol Biochem Behav. 1996;55(3):365–9.PubMedCrossRef
17.
Zurück zum Zitat Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;154(2):366–75e4.PubMedCrossRef Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;154(2):366–75e4.PubMedCrossRef
18.
Zurück zum Zitat Mudvari SS, Goff MJ, Fu AD, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27(9):1168–73.PubMedCrossRef Mudvari SS, Goff MJ, Fu AD, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27(9):1168–73.PubMedCrossRef
19.
Zurück zum Zitat Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96(6):854–9.PubMedCrossRef Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96(6):854–9.PubMedCrossRef
20.
Zurück zum Zitat Framme C, Walter A, Gabler B, et al. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83(2):161–7.PubMedCrossRef Framme C, Walter A, Gabler B, et al. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83(2):161–7.PubMedCrossRef
21.
Zurück zum Zitat Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23(1):1–7. (quiz 137-8).PubMedCrossRef Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23(1):1–7. (quiz 137-8).PubMedCrossRef
22.
Zurück zum Zitat Quaranta-El Maftouhi M, Maftouhi A E, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol. 2015;160(3):581–7.PubMedCrossRef Quaranta-El Maftouhi M, Maftouhi A E, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol. 2015;160(3):581–7.PubMedCrossRef
23.
Zurück zum Zitat Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995;102(5):737–47.PubMedCrossRef Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995;102(5):737–47.PubMedCrossRef
24.
Zurück zum Zitat Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1):65–74.PubMedCrossRef Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1):65–74.PubMedCrossRef
25.
Zurück zum Zitat Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol. 2000;129(1):16–20.PubMedCrossRef Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol. 2000;129(1):16–20.PubMedCrossRef
26.
Zurück zum Zitat Nicolo M, Zoli D, Musolino M, Traverso CE. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol. 2012;153(3):474–80e1.PubMedCrossRef Nicolo M, Zoli D, Musolino M, Traverso CE. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol. 2012;153(3):474–80e1.PubMedCrossRef
27.
Zurück zum Zitat Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, et al. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int. J Ophthalmol. 2014;7(2):350–4. Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, et al. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int. J Ophthalmol. 2014;7(2):350–4.
28.
Zurück zum Zitat Yalcinbayir O, Gelisken O, Akova-Budak B, et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina. 2014;34(4):705–12.PubMed Yalcinbayir O, Gelisken O, Akova-Budak B, et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina. 2014;34(4):705–12.PubMed
29.
Zurück zum Zitat Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology. 2005;112(5):825–33.PubMedCrossRef Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology. 2005;112(5):825–33.PubMedCrossRef
30.
Zurück zum Zitat Eandi CM, Piccolino FC, Alovisi C, et al. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159(4):652–8.PubMedCrossRef Eandi CM, Piccolino FC, Alovisi C, et al. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159(4):652–8.PubMedCrossRef
31.
Zurück zum Zitat Iacono P, Battaglia PM, Papayannis A, et al. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1889–97.PubMedCrossRef Iacono P, Battaglia PM, Papayannis A, et al. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1889–97.PubMedCrossRef
32.
Zurück zum Zitat Yoshioka H, Endo Y, Sugita T. [The study of central serous chorioretinopathy by fluorescein fundus angiography. (I)]. Nihon Ganka Gakkai Zasshi. 1969;73(3):299–305.PubMed Yoshioka H, Endo Y, Sugita T. [The study of central serous chorioretinopathy by fluorescein fundus angiography. (I)]. Nihon Ganka Gakkai Zasshi. 1969;73(3):299–305.PubMed
33.
Zurück zum Zitat Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9(1):37–41.PubMedCrossRef Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9(1):37–41.PubMedCrossRef
34.
Zurück zum Zitat Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231–42.PubMedCrossRef Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231–42.PubMedCrossRef
35.
Zurück zum Zitat Lafaut BA, De Laey JJ. Indocyanine green angiography in central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 1996;262:55–61.PubMed Lafaut BA, De Laey JJ. Indocyanine green angiography in central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 1996;262:55–61.PubMed
36.
Zurück zum Zitat Shiraki K, Moriwaki M, Matsumoto M, et al. Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol. 1997;21(5):245–53.PubMedCrossRef Shiraki K, Moriwaki M, Matsumoto M, et al. Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol. 1997;21(5):245–53.PubMedCrossRef
37.
Zurück zum Zitat Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with Verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453–8.PubMedCentralPubMedCrossRef Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with Verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453–8.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Zeligs MA. Central angiospastic retinopathy; a psychosomatic study of its occurrence in military personnel. Psychosom Med. 1947;9(2):110–7.PubMedCrossRef Zeligs MA. Central angiospastic retinopathy; a psychosomatic study of its occurrence in military personnel. Psychosom Med. 1947;9(2):110–7.PubMedCrossRef
39.
Zurück zum Zitat Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics. 1971;12(6):398–401.PubMedCrossRef Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics. 1971;12(6):398–401.PubMedCrossRef
40.
Zurück zum Zitat Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch Clin Exp Ophthalmol. 1998;236(8):571–6.PubMedCrossRef Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch Clin Exp Ophthalmol. 1998;236(8):571–6.PubMedCrossRef
41.
Zurück zum Zitat Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006;47(8):3474–8.PubMedCrossRef Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006;47(8):3474–8.PubMedCrossRef
42.
Zurück zum Zitat Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995;79(10):922–5.PubMedCentralPubMedCrossRef Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995;79(10):922–5.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46(3):160–3.PubMedCrossRef Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46(3):160–3.PubMedCrossRef
44.
Zurück zum Zitat Werry H, Arends C. Untersuchung zur Objektivierung von Persönlichkeitsmerkmalen bei Patienten mit Retinopathia centralis serosa. Klin Monatsbl Augenheilkd. 1978;172(3):363–70.PubMed Werry H, Arends C. Untersuchung zur Objektivierung von Persönlichkeitsmerkmalen bei Patienten mit Retinopathia centralis serosa. Klin Monatsbl Augenheilkd. 1978;172(3):363–70.PubMed
45.
46.
Zurück zum Zitat Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):704–8.PubMedCentralPubMedCrossRef Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):704–8.PubMedCentralPubMedCrossRef
47.
Zurück zum Zitat Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014;2014:631687.PubMedCentralPubMedCrossRef Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014;2014:631687.PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):456–67.PubMed Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):456–67.PubMed
49.
Zurück zum Zitat Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–66.PubMedCrossRef Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–66.PubMedCrossRef
50.
51.
Zurück zum Zitat Nomura Y, Obata R, Yanagi Y. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56(3):245–9.PubMedCrossRef Nomura Y, Obata R, Yanagi Y. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56(3):245–9.PubMedCrossRef
52.
Zurück zum Zitat Cakir M, Cekic O, Yilmaz OF. Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(4):405–8.PubMedCrossRef Cakir M, Cekic O, Yilmaz OF. Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(4):405–8.PubMedCrossRef
53.
Zurück zum Zitat Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–34.PubMedCrossRef Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–34.PubMedCrossRef
54.
Zurück zum Zitat Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–40.PubMed Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–40.PubMed
55.
Zurück zum Zitat Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–5.PubMedCrossRef Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–5.PubMedCrossRef
56.
Zurück zum Zitat Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012;26(2):307–14.CrossRef Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012;26(2):307–14.CrossRef
57.
Zurück zum Zitat Roisman L, Magalhaes FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):465–70.PubMedCrossRef Roisman L, Magalhaes FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):465–70.PubMedCrossRef
58.
Zurück zum Zitat Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35(3):532–6.PubMedCrossRef Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35(3):532–6.PubMedCrossRef
59.
Zurück zum Zitat Framme C, Alt C, Schnell S, Brinkmann R, Lin CP. [Selective RPE laser treatment with a scanned cw laser beam in rabbits]. Ophthalmologe. 2005;102(5):491–6.PubMedCrossRef Framme C, Alt C, Schnell S, Brinkmann R, Lin CP. [Selective RPE laser treatment with a scanned cw laser beam in rabbits]. Ophthalmologe. 2005;102(5):491–6.PubMedCrossRef
60.
Zurück zum Zitat Elsner H, Porksen E, Klatt C, et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1638–45.PubMedCrossRef Elsner H, Porksen E, Klatt C, et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1638–45.PubMedCrossRef
61.
Zurück zum Zitat Klatt C, Elsner H, Porksen E, et al. [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium]. Ophthalmologe. 2006;103(10):850–5.PubMedCrossRef Klatt C, Elsner H, Porksen E, et al. [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium]. Ophthalmologe. 2006;103(10):850–5.PubMedCrossRef
62.
Zurück zum Zitat Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R. Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med. 2008;40(9):616–24.PubMedCrossRef Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R. Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med. 2008;40(9):616–24.PubMedCrossRef
63.
Zurück zum Zitat Klatt C, Saeger M, Oppermann T, et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011;95(1):83–8.PubMedCrossRef Klatt C, Saeger M, Oppermann T, et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011;95(1):83–8.PubMedCrossRef
64.
Zurück zum Zitat Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–98.PubMedCrossRef Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–98.PubMedCrossRef
65.
Zurück zum Zitat Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752–63.PubMedCrossRef Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752–63.PubMedCrossRef
66.
Zurück zum Zitat Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136(4):750–2.PubMedCrossRef Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136(4):750–2.PubMedCrossRef
67.
Zurück zum Zitat Battaglia Parodi M, Pozzo S D, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003;23(2):235–7.PubMedCrossRef Battaglia Parodi M, Pozzo S D, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003;23(2):235–7.PubMedCrossRef
68.
Zurück zum Zitat Rouvas A, Stavrakas P, Theodossiadis PG, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22(3):417–22.PubMedCrossRef Rouvas A, Stavrakas P, Theodossiadis PG, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22(3):417–22.PubMedCrossRef
69.
Zurück zum Zitat Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond). 2013;27(5):612–20.CrossRef Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond). 2013;27(5):612–20.CrossRef
70.
Zurück zum Zitat Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697–705.PubMedCrossRef Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697–705.PubMedCrossRef
71.
Zurück zum Zitat Gutierrez-Hernandez JC, Martinez-Camarillo JC, Sadda SR. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2015;9(2):109–13.PubMedCrossRef Gutierrez-Hernandez JC, Martinez-Camarillo JC, Sadda SR. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2015;9(2):109–13.PubMedCrossRef
72.
Zurück zum Zitat Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol. 2015;99(8):1070–7.PubMedCrossRef Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol. 2015;99(8):1070–7.PubMedCrossRef
73.
Zurück zum Zitat Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011;89(3):e293–4.PubMedCrossRef Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011;89(3):e293–4.PubMedCrossRef
74.
Zurück zum Zitat Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152(5):784–92e2.PubMedCrossRef Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152(5):784–92e2.PubMedCrossRef
75.
Zurück zum Zitat Zhao M, Zhang F, Chen Y, et al. A 50 % vs 30 % dose of Verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333–40.PubMedCrossRef Zhao M, Zhang F, Chen Y, et al. A 50 % vs 30 % dose of Verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333–40.PubMedCrossRef
76.
Zurück zum Zitat Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594–601.PubMedCrossRef Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594–601.PubMedCrossRef
77.
Zurück zum Zitat Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: a case series. Oman. J Ophthalmol. 2011;4(2):63–6. Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: a case series. Oman. J Ophthalmol. 2011;4(2):63–6.
78.
Zurück zum Zitat Smretschnig E, Ansari-Shahrezaei S, Moussa S, et al. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012;32(10):2014–9.PubMedCrossRef Smretschnig E, Ansari-Shahrezaei S, Moussa S, et al. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012;32(10):2014–9.PubMedCrossRef
79.
Zurück zum Zitat Lim SH, Chang W, Sagong M. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond). 2013;27(3):353–62.CrossRef Lim SH, Chang W, Sagong M. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond). 2013;27(3):353–62.CrossRef
80.
Zurück zum Zitat Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157(5):1033–7.PubMedCrossRef Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157(5):1033–7.PubMedCrossRef
81.
Zurück zum Zitat Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose Verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65.PubMedCrossRef Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose Verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65.PubMedCrossRef
82.
Zurück zum Zitat Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93.PubMedCrossRef Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93.PubMedCrossRef
83.
Zurück zum Zitat Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose Verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30(10):1698–703.PubMedCrossRef Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose Verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30(10):1698–703.PubMedCrossRef
84.
Zurück zum Zitat Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014;157(2):366–73e1.PubMedCrossRef Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014;157(2):366–73e1.PubMedCrossRef
85.
Zurück zum Zitat Shiode Y, Morizane Y, Kimura S, et al. Comparison of halving the irradiation time or the Verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2015. (Epub ahead of print). Shiode Y, Morizane Y, Kimura S, et al. Comparison of halving the irradiation time or the Verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2015. (Epub ahead of print).
86.
Zurück zum Zitat Kim YK, Ryoo NK, Woo SJ, Park KH. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print). Kim YK, Ryoo NK, Woo SJ, Park KH. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).
87.
Zurück zum Zitat Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013;33(2):309–15.PubMedCrossRef Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013;33(2):309–15.PubMedCrossRef
88.
Zurück zum Zitat Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073–8.PubMedCrossRef Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073–8.PubMedCrossRef
89.
Zurück zum Zitat Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2007(303):69–73. Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2007(303):69–73.
90.
Zurück zum Zitat Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006;22(2):145–9.PubMedCrossRef Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006;22(2):145–9.PubMedCrossRef
91.
Zurück zum Zitat Fabianova J, Porubska M, Cepilova Z. [Central serous chorioretinopathy-treatment with beta blockers]. Cesk Slov Oftalmol. 1998;54(6):401–4.PubMed Fabianova J, Porubska M, Cepilova Z. [Central serous chorioretinopathy-treatment with beta blockers]. Cesk Slov Oftalmol. 1998;54(6):401–4.PubMed
92.
Zurück zum Zitat Chrapek O, Spackova K, Rehak J. [Treatment of central serous chorioretinopathy with beta blockers]. Cesk Slov Oftalmol. 2002;58(6):382–6.PubMed Chrapek O, Spackova K, Rehak J. [Treatment of central serous chorioretinopathy with beta blockers]. Cesk Slov Oftalmol. 2002;58(6):382–6.PubMed
93.
Zurück zum Zitat Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):120–3.PubMed Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):120–3.PubMed
94.
Zurück zum Zitat Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899–903.PubMedCentralPubMedCrossRef Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899–903.PubMedCentralPubMedCrossRef
95.
96.
Zurück zum Zitat Chong CF, Yang D, Pham TQ, Liu H. A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. 2012;2012:pii. Chong CF, Yang D, Pham TQ, Liu H. A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. 2012;2012:pii.
97.
Zurück zum Zitat Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2013;2(4):96–101.PubMedCentralPubMed Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2013;2(4):96–101.PubMedCentralPubMed
98.
Zurück zum Zitat Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–5.PubMedCrossRef Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–5.PubMedCrossRef
99.
Zurück zum Zitat Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31(9):1928–36.PubMedCrossRef Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31(9):1928–36.PubMedCrossRef
100.
Zurück zum Zitat Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Brief Rep. 2012;6(1):129–32.PubMedCrossRef Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Brief Rep. 2012;6(1):129–32.PubMedCrossRef
101.
Zurück zum Zitat Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014;8(1):70–2.PubMedCrossRef Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014;8(1):70–2.PubMedCrossRef
102.
Zurück zum Zitat Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print). Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).
103.
Zurück zum Zitat Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31(4):766–71.PubMedCentralPubMed Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31(4):766–71.PubMedCentralPubMed
104.
Zurück zum Zitat Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015. (Epub ahead of print). Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015. (Epub ahead of print).
105.
Zurück zum Zitat Ryan EH, Pulido CM. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Retin Cases Brief Rep. 2015;9(3):235–8.PubMedCrossRef Ryan EH, Pulido CM. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Retin Cases Brief Rep. 2015;9(3):235–8.PubMedCrossRef
106.
Zurück zum Zitat Singh RP, Sears JE, Bedi R, et al. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int. J Ophthalmol. 2015;8(2):310–4. Singh RP, Sears JE, Bedi R, et al. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int. J Ophthalmol. 2015;8(2):310–4.
107.
Zurück zum Zitat Salz DA, Pitcher JD 3rd, Hsu J, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):439–44.PubMedCrossRef Salz DA, Pitcher JD 3rd, Hsu J, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):439–44.PubMedCrossRef
108.
Zurück zum Zitat Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92(6):e488–90.PubMedCrossRef Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92(6):e488–90.PubMedCrossRef
109.
Zurück zum Zitat Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977–83.PubMedCrossRef Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977–83.PubMedCrossRef
110.
Zurück zum Zitat Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27(12):1339–46.CrossRef Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27(12):1339–46.CrossRef
111.
Zurück zum Zitat Kim DY, Joe SG, Yang SJ, et al. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean J Ophthalmol. 2015;29(3):160–7.PubMedCentralPubMedCrossRef Kim DY, Joe SG, Yang SJ, et al. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean J Ophthalmol. 2015;29(3):160–7.PubMedCentralPubMedCrossRef
112.
Zurück zum Zitat Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015;29(6):732–40. (quiz 41).CrossRef Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015;29(6):732–40. (quiz 41).CrossRef
113.
Zurück zum Zitat Altun A, Kurna SA, Olcaysu OO, et al. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab. J Ocul Pharmacol Ther. 2014;30(10):842–6.PubMedCrossRef Altun A, Kurna SA, Olcaysu OO, et al. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab. J Ocul Pharmacol Ther. 2014;30(10):842–6.PubMedCrossRef
114.
Zurück zum Zitat Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848–52.PubMedCrossRef Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848–52.PubMedCrossRef
115.
Zurück zum Zitat Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):979–81.PubMedCrossRef Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):979–81.PubMedCrossRef
116.
Zurück zum Zitat Cunneen TS, Tridgell D. The dexamethasone suppression test for the diagnosis of Cushing syndrome in a patient with central serous chorioretinopathy. Retin Cases Brief Rep. 2013;7(2):143–5.PubMedCrossRef Cunneen TS, Tridgell D. The dexamethasone suppression test for the diagnosis of Cushing syndrome in a patient with central serous chorioretinopathy. Retin Cases Brief Rep. 2013;7(2):143–5.PubMedCrossRef
Metadaten
Titel
Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa
verfasst von
a. Univ. Prof. Dr. Michael Stur
Siamak Ansari-Shahrezaei
Anton Haas
Michael Tittl
Publikationsdatum
01.02.2016
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 1/2016
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-015-0276-3

Weitere Artikel der Ausgabe 1/2016

Spektrum der Augenheilkunde 1/2016 Zur Ausgabe